AstraZeneca’s durvalumab was granted FDA orphan designation for the treatment of gastric cancer, including gastroesophageal junction cancer, according to a post to the agency’s website.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on AZN:
- Unusually active option classes on open October 18th
- Meharry Medical College, partners launch Together for CHANGE initiative
- Sophia Genetics announces collaboration with MSK Cancer Center and AstraZeneca
- AstraZeneca says Soliris approved in China for treatment of adults with NMOSD
- Johnson & Johnson (NYSE:JNJ) Slips despite Cancer Drug Win